Compare LOOP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | TLSA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 145.1M |
| IPO Year | 2010 | 2017 |
| Metric | LOOP | TLSA |
|---|---|---|
| Price | $0.47 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 235.8K | ★ 520.5K |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,889,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $174.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7016.99 | N/A |
| 52 Week Low | $0.41 | $0.76 |
| 52 Week High | $1.99 | $2.35 |
| Indicator | LOOP | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.22 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $1.20 |
| Average True Range (ATR) | 0.00 | 0.08 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 42.61 |
Loop Industries Inc is a technology company whose mission is to accelerate the world's shift toward sustainable PET plastic and polyester fiber and away from dependence on fossil fuels. Loop Industries owns patented and proprietary technology that depolymerizes no and low-value waste PET plastic and polyester fiber, including plastic bottles, packaging, and textiles such as carpets and clothing, into its base building block monomers, DMT and MEG.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.